


Research shows bulevirtide and peginterferon alfa-2a best treatment for chronic hepatitis D

June 10 2024, by Lori Solomon





The combination of bulevirtide plus peginterferon alfa-2a is superior to bulevirtide monotherapy for achieving undetectable hepatitis D virus (HDV) RNA level at 24 weeks after the end of treatment in patients with chronic hepatitis D, according to a study <u>published</u> online June 6 in the *New England Journal of Medicine* to coincide with the annual congress of the European Association for the Study of the Liver, held from June 5 to 8 in Milan.

Tarik Asselah, M.D., Ph.D., from Université de Paris-Cité, and colleagues conducted a phase 2b trial in which patients with chronic hepatitis D were randomly assigned to peginterferon alfa-2a alone (180 µg per week) for 48 weeks (24 patients); bulevirtide (daily dose of 2 mg or 10 mg) plus peginterferon alfa-2a (180 µg per week) for 48 weeks (50 patients at each dose), followed by the same daily dose of bulevirtide for 48 weeks; or bulevirtide alone (daily dose of 10 mg) for 96 weeks (50 patients).

The researchers found that 24 weeks after the end of treatment, HDV RNA was undetectable in 17% of the patients in the peginterferon alfa-2a group, 32% of those in the 2-mg bulevirtide plus peginterferon alfa-2a group, 46% of those in the 10-mg bulevirtide plus peginterferon alfa-2a group, and 12% of those in the 10-mg bulevirtide group.

For the primary comparison between the 10-mg bulevirtide plus peginterferon alfa-2a group and the 10-mg bulevirtide monotherapy group, the between-group difference was 34 percentage points. At 48 weeks after the end of treatment, the percentage of patients with HDV RNA that was undetectable was 25, 26, 46, and 12%, respectively, in the four study arms. Most adverse events were grade 1 or 2, and the most frequent were leukopenia, neutropenia, and thrombocytopenia.



"Our results indicate that a regimen of finite duration for chronic hepatitis D led to a sustained undetectable HDV RNA response, as measured by a highly sensitive HDV RNA assay, beyond 24 weeks after the end of <u>treatment</u>," the authors write.

More information: Tarik Asselah et al, Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D, *New England Journal of Medicine* (2024). DOI: 10.1056/NEJMoa2314134

Norah Terrault, Treatment of Hepatitis D—A Future Role for Combination Therapy, *New England Journal of Medicine* (2024). DOI: 10.1056/NEJMe2406180

© 2024 <u>HealthDay</u>. All rights reserved.

Citation: Research shows bulevirtide and peginterferon alfa-2a best treatment for chronic hepatitis D (2024, June 10) retrieved 18 June 2024 from https://medicalxpress.com/news/2024-06-bulevirtide-peginterferon-alfa-2a-treatment.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.